NCT06636123View on ClinicalTrials.gov

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2031

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

Investigational Agent Administration

GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity

Trial Locations (1)

23298

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER